{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:54:09Z","timestamp":1777578849165,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate efficacy, safety and quality of life in ocular hypertensive or open-angle glaucoma patients changed to latanoprost from previous therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective, multicenter, active-controlled design in which qualified patients had their previous therapy substituted for latanoprost and were followed for at least thee months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 1068 patients, latanoprost was continued 92% throughout the 36-month observation period. Latanoprost treatment reduced the intraocular pressure (IOP)(p &lt; 0.001) when compared to previous monotherapies including: beta-blockers (-4.0 \u00b1 3.7 mmHg, 42%), alpha-antagonists (-3.9 \u00b1 3.0 mmHg, 14%), miotics (-3.8 \u00b1 3.5 mmHg, 2%), or carbonic anhydrase inhibitors (CAI) (-3.8 \u00b1 3.6 mmHg, n = 16%), and adjunctive therapy including: beta-blocker and CAI (-3.7 \u00b1 3.1 mmHg, n = 12%), alpha-agonist (-3.7 \u00b1 3.4 mmHg, n = 5%), or pilocarpine (-3.4 \u00b1 3.7 mmHg, n = 6%), or CAI and alpha-agonist (-4.6 \u00b1 6.4 mm Hg, n = 2%)(p &lt; 0.0017). The most common adverse event with latanoprost was ocular allergy (1.5% incidence). Patients showed a preference for latanoprost for many systemic and ocular quality of life measures on a non-validated questionnaire (p &lt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a clinical setting, patients who have their mono- and adjunctive therapy treatment substituted for latanoprost may on average experience reduced IOP, deceased side effects and increased quality of life measures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/112067210401400508","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:42:51Z","timestamp":1516322571000},"page":"407-415","source":"Crossref","is-referenced-by-count":21,"title":["Intraocular Pressure, Safety and Quality of Life in Glaucoma Patients Switching to Latanoprost from Adjunctive and Monotherapy Treatments"],"prefix":"10.1177","volume":"14","author":[{"given":"F.","family":"Haverkamp","sequence":"first","affiliation":[{"name":"Children's Hospital at the University of Bonn, Bonn"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Wuensch","sequence":"additional","affiliation":[{"name":"Pfizer GmbH, Erlangen - Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Pfizer GmbH, Erlangen - Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. C.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Network, LLC, Charleston, SC"},{"name":"Carolina Eye Institute at the University of South Carolina School of Medicine, Columbia, SC -USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2004,9,1]]},"reference":[{"key":"bibr1-112067210401400508","first-page":"117","volume-title":"Testing statistical hypotheses.","author":"Book S.A.","year":"1978"},{"key":"bibr2-112067210401400508","unstructured":"SiegelS. Non parametric statistics. Series in psychology. New York: McGraw-Hill Book Company, 1956; 63\u20137."},{"key":"bibr3-112067210401400508","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(95)30798-1"},{"key":"bibr4-112067210401400508","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30749-5"},{"key":"bibr5-112067210401400508","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30750-1"},{"key":"bibr6-112067210401400508","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00902-8"},{"key":"bibr7-112067210401400508","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(00)00495-4"},{"key":"bibr8-112067210401400508","first-page":"S665","volume":"40","author":"Fechtner R.","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bibr9-112067210401400508","first-page":"S420","volume":"42","author":"Konstas A.G.P.","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bibr10-112067210401400508","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(01)00212-0"},{"key":"bibr11-112067210401400508","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01177-1"},{"key":"bibr12-112067210401400508","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(02)00328-4"},{"key":"bibr13-112067210401400508","first-page":"117","volume":"9","author":"Stewart W.C.","year":"2002","journal-title":"Rev Ophthalmol"},{"key":"bibr14-112067210401400508","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(02)00329-6"},{"key":"bibr15-112067210401400508","first-page":"S256","volume":"38","author":"Clifford T.B.","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bibr16-112067210401400508","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2000.16.557"},{"key":"bibr17-112067210401400508","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)70865-7"},{"key":"bibr18-112067210401400508","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200006000-00005"},{"key":"bibr19-112067210401400508","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200010000-00009"},{"key":"bibr20-112067210401400508","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00874-0"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/112067210401400508","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/112067210401400508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:35:50Z","timestamp":1777404950000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/112067210401400508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1177\/112067210401400508"],"URL":"https:\/\/doi.org\/10.1177\/112067210401400508","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}